PALI Stock — Palisade Bio Inc.: Cash, EV, Pipeline

What they do

Our lead clinical product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (“IBD”), including ulcerative colitis (“UC”) and Crohn’s disease (“CD”). Our Strategy We are committed to advancing a next generation of once daily, oral PDE4 inhibitor prodrugs to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.13

Market cap

$196.9M

Cash

$125.2M

Enterprise value

$71.7M

Balance sheet

Cash	$125.2M
Debt	$0.0M
Net cash	$125.2M
Enterprise value	$71.7M
Basic shares	174.3M shares
Fully diluted shares	258.1M shares
Fully diluted market cap	$291.7M
Cash per share	$0.72
Quarterly burn	$7.6M
Cash runway	16.5 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

174.3M

Pre-funded warrants

37.8M

Options

0.2M

RSUs

32.0M

Warrants

13.8M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

258.1M

Cap table as of 2026-06-30.

Price history

Loading PALI daily closes…

Loading price history…

Next catalyst

PALI-2108 · Est. Sep 30, 2027 · half midpoint · guided in 8 mo

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Sep 30, 2027 in 8 mo half midpoint	PALI-2108 ASCENTRA-UC global Phase 2b in moderately to severely active ulcerative colitis, primary efficacy results from 12-week induction	Phase 2b	moderately to severely active ulcerative colitis	H2 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

PALI-2108

Phase 2 · Active Modality: oral prodrug (targeted PDE4 inhibition via lower-intestinal bacterial bioactivation)

Target PDE4

Partnerships Giiant: exclusive worldwide license (September 2023) to PALI-2108 and PALI-1908; development milestones and mid-single-digit royalties on sales/sublicenses. Crohn's & Colitis Foundation: up to $0.5M funding for Phase 1b program

Indications

Ulcerative colitis (moderately-to-severely active) (Phase 2)
Crohn's disease (including fibrostenotic) (Phase 1)

Catalysts

— H2 2026
— H2 2026

Status note Lead candidate. Phase 1 program completed H1 2026 (106 subjects; positive Phase 1b FSCD cohort data reported March 30, 2026). ASCENTRA-UC: randomized, placebo-controlled Phase 2 in ~204 patients (15/30 mg QD). ASCENTRA-CD Phase 2 planned.

PALI-1908

Stage not disclosed · Active

Partnerships Giiant: exclusive worldwide license (September 2023)

Status note Giiant licensed asset; no development details disclosed in excerpts.

NSI-532.IGF-1

Preclinical · Active Modality: cell therapy (preclinical)

Partnerships University of Michigan: exclusive license for continued development and licensing (October 2022); Palisade receives 50% of net licensing revenues

Status note Preclinical cell therapy investigated for prevention and treatment of Alzheimer's disease; development costs borne by the university.

LB1148

Stage not disclosed · Terminated

Status note Development terminated October 20, 2023; two of three UC Regents license agreements terminated (2015 UC license retained for Newsoara co-development).

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	PALI-2108
Lead indication	Ulcerative Colitis (UC)
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07428096	Phase 1	Active, not recruiting	Sponsor	PALI	—	Fibrostenotic Crohn's Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Palisade Bio on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	8,425,065	-503,084	0.27%	2026-08-14
RA Capital Management	7,124,116	no change	0.13%	2026-08-14
Boxer Capital	4,799,875	no change	0.76%	2026-08-14
OrbiMed Advisors	2,333,000	no change	0.09%	2026-08-14
Great Point Partners	2,284,819	-1,120,938	1.13%	2026-08-14
Sphera Biotech	2,257,106	+523,635	0.68%	2026-08-14
ADAR1 Capital Management	1,726,662	-538,183	0.17%	2026-08-14
Ally Bridge Group	1,229,000	+1,229,000	3.31%	2026-08-14
Ikarian Capital	750,000	+475,022	0.26%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

PALI — Palisade Bio Inc. ☆